Mixed Phenotype Acute Leukemia (MPAL): Understanding This Rare Blood Cancer

Mixed Phenotype Acute Leukemia (MPAL) is a rare and complex form of leukemia that presents a diagnostic and treatment challenge due to its unique characteristics. Unlike typical acute leukemias, which originate from either lymphoid or myeloid cell lineages, MPAL exhibits features of both. This dual nature means that leukemia cells in MPAL possess markers typically found on both lymphoid and myeloid cells, making it difficult to classify and manage effectively. In India, as globally, understanding MPAL is crucial for timely diagnosis and appropriate care. What is Mixed Phenotype Acute Leukemia (MPAL)? Acute leukemias are broadly categorized into two main types based on the origin of the cancerous cells: Acute Lymphocytic Leukemia (ALL): This type originates from lymphoid cells, which are precursors to white blood cells like B cells and T cells. Acute Myeloid Leukemia (AML): This type originates from myeloid cells, which develop into various white blood cells such as neutrophils and monocytes, as well as red blood cells and platelets. MPAL, however, blurs these lines. It is a type of acute leukemia where the cancerous cells display characteristics of both lymphoid and myeloid lineages. This can manifest in two primary ways: Bilineal MPAL: This subtype involves two distinct populations of leukemia cells. One population shows lymphoid markers, while the other shows myeloid markers. The term 'bilineal' signifies these two separate lineages. Biphenotypic MPAL: In this subtype, a single population of leukemia cells expresses markers from both lymphoid and myeloid lineages simultaneously. The term 'biphenotypic' refers to this dual expression. It's important to note that the distinction between these two subtypes is not always rigid. In some cases, bilineal MPAL can transform into biphenotypic MPAL, and vice versa, adding to the complexity of this condition. MPAL is a rare condition, accounting for a small percentage of all acute leukemias. It is estimated to make up about 1% to 3% of adult acute leukemias and less than 5% of pediatric acute leukemias. Its rarity means that awareness among the general public and even some healthcare professionals might be limited, underscoring the need for greater understanding. Symptoms of MPAL The symptoms of MPAL are generally similar to those experienced in other forms of acute leukemia. These symptoms arise due to the rapid proliferation of cancerous white blood cells, which crowd out healthy blood cells in the bone marrow, leading to deficiencies in red blood cells, normal white blood cells, and platelets. Common symptoms include: Anemia-related symptoms: Due to a low red blood cell count, individuals may experience: Fatigue and persistent tiredness Weakness Dizziness or lightheadedness Shortness of breath, especially during exertion Infection-related symptoms: A shortage of healthy white blood cells makes the body vulnerable to infections. This can lead to frequent or severe infections, fevers, and chills. Bleeding-related symptoms: A low platelet count can result in easy bruising, prolonged bleeding from cuts, nosebleeds, bleeding gums, and petechiae (small red or purple spots on the skin caused by bleeding under the skin). Other potential symptoms: Some individuals may also experience bone pain, swollen lymph nodes, or an enlarged spleen or liver, which can cause abdominal discomfort or fullness. It is crucial to remember that these symptoms can also be indicative of many other less severe conditions. However, if these symptoms are persistent or severe, seeking medical attention is essential. Causes of MPAL The exact cause of MPAL, like many other types of leukemia, is not fully understood. Generally, leukemia develops when there are genetic mutations in the DNA of blood stem cells within the bone marrow. These mutations cause the stem cells to grow uncontrollably and fail to mature into healthy blood cells. Instead, they accumulate as leukemia cells. While the specific triggers for these mutations in MPAL are unknown, certain genetic abnormalities have been identified in individuals with this condition. These include: Philadelphia Chromosome (Ph): This is a specific genetic mutation where parts of chromosome 9 and chromosome 22 swap places. This results in the fusion of the BCR and ABL1 genes on chromosome 22, which is a known driver of certain leukemias. MPAL with the Philadelphia chromosome (MPAL with t(9;22)(q34;q11.2); BCR-ABL1) is one subtype. Chromosome 11q23 Abnormalities: These involve alterations to a specific region on chromosome 11, known as 11q23. MPAL associated with these abnormalities is termed MPAL with t(v;11q23); KMT2A rearranged. There are also subtypes of MPAL that do not have these specific chromosomal abnormalities, referred to as MPAL B-myeloid, NOS (not otherwise specified) and MPAL T-myeloid, NOS, depending on the lymphoid lineage (B or T) and myeloid markers present. Research suggests that certain factors might increase the risk of developing leukemia, although they are not direct causes. These can include exposure to certain chemicals (like benzene), radiation, and a history of other blood disorders. However, for MPAL, these risk factors are less clearly defined than for some other leukemias. Diagnosis of MPAL Diagnosing MPAL can be challenging due to its mixed characteristics. A thorough diagnostic process is essential to accurately identify the type of leukemia and guide treatment. The diagnostic process typically involves: Physical Examination and Medical History: A doctor will inquire about symptoms, family history, and perform a physical exam to check for signs like swollen lymph nodes or enlarged spleen/liver. Blood Tests: A complete blood count (CBC) can reveal abnormalities in the number of red blood cells, white blood cells, and platelets. Blood smear examination can provide initial clues about the presence of abnormal cells. Bone Marrow

In summary, timely diagnosis, evidence-based treatment, and prevention-focused care improve long-term health outcomes.